Physician profile
Kunil Bae
NPI 1295765378
$25,083.25
in general payments reported to CMS, 2019-2025
36 companies · $2,414 in 2025
The $2,414 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,485 · 2020: $2,421 · 2021: $4,035 · 2022: $3,386 · 2023: $2,896 · 2024: $2,447 · 2025: $2,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,756.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $6,579.73 | 2019-2025 | Evenity, Repatha, Repatha |
| Gilead Sciences, INC. | $2,969.19 | 2019-2025 | Vemlidy |
| Abbvie INC. | $2,058.87 | 2019-2025 | Linzess, Creon, Viberzi |
| Novo Nordisk INC | $1,527.21 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,121.46 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $1,030.74 | 2019-2023 | |
| Nestle Healthcare Nutrition INC. | $998.18 | 2020-2023 | |
| Ardelyx, INC. | $868.05 | 2022-2025 | Ibsrela |
| Astrazeneca Pharmaceuticals Lp | $801.10 | 2020-2024 | Calquence, Tagrisso, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $739.45 | 2021-2025 | |
| Lilly USA, LLC | $645.38 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $635.21 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $512.45 | 2020-2024 | Linzess |
| Allergan, INC. | $490.23 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $481.63 | 2019-2023 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kunil Bae listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.